PRLD - Prelude Therapeutics Inc

PRLD - Prelude Therapeutics Inc

https://preludetx.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences

GlobeNewswire • 3 months, 1 week ago • score: 0.05

WILMINGTON, Del., June 02, 2025 ( GLOBE NEWSWIRE ) -- Prelude Therapeutics Incorporated ( Prelude ) ( Nasdaq: PRLD ) , a clinical-stage precision oncology company, announced today that the Company will participate in two upcoming healthcare conferences in June.

Prelude Therapeutics to Participate in Citizens Life Sciences Conference - Prelude Therapeutics ( NASDAQ:PRLD )

Benzinga • 4 months, 2 weeks ago • score: -0.04

WILMINGTON, Del., May 01, 2025 ( GLOBE NEWSWIRE ) -- Prelude Therapeutics Incorporated ( Prelude ) PRLD, a clinical-stage precision oncology company, announced today that the Company will participate in the Citizens Life Sciences Conference taking place in New York on May 7, 2025.

Prelude Therapeutics to Participate in Citizens Life Sciences Conference

GlobeNewswire • 4 months, 2 weeks ago • score: 0.02

WILMINGTON, Del., May 01, 2025 ( GLOBE NEWSWIRE ) -- Prelude Therapeutics Incorporated ( Prelude ) ( Nasdaq: PRLD ) , a clinical-stage precision oncology company, announced today that the Company will participate in the Citizens Life Sciences Conference taking place in New York on May 7, 2025.

Prelude Therapeutics ( PRLD ) Upgraded to Buy: Here's What You Should Know

Zacks Commentary • 5 months ago • score: 0.30

Prelude Therapeutics (PRLD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Prelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare Conference - Prelude Therapeutics ( NASDAQ:PRLD )

Benzinga • 6 months, 1 week ago • score: -0.04

WILMINGTON, Del., March 05, 2025 ( GLOBE NEWSWIRE ) -- Prelude Therapeutics Incorporated ( Prelude ) PRLD, a clinical-stage precision oncology company, announced today that the Company will participate in the Barclays 27th Annual Global Healthcare Conference, taking place in Miami, FL on March ...

Prelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare Conference

GlobeNewswire • 6 months, 1 week ago • score: 0.02

WILMINGTON, Del., March 05, 2025 ( GLOBE NEWSWIRE ) -- Prelude Therapeutics Incorporated ( Prelude ) ( Nasdaq: PRLD ) , a clinical-stage precision oncology company, announced today that the Company will participate in the Barclays 27th Annual Global Healthcare Conference, taking place in Miami, ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Prelude Therapeutics Incorporated, a precision clinical-stage oncology company, focuses on the discovery and development of small molecule therapies optimized to target key drivers in cancers. The company is headquartered in Wilmington, Delaware.

52W High

$5.53

52W Low

$0.61

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.24

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-0.54

EV/Revenue (<3 favorable)

2.05

P/S (TTM) (<3 favorable)

9.95

P/B (<3 favorable)

0.92

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

11.34%

Institutions (25–75% balanced)

62.34%

Shares Outstanding

43,750,100

Float

29,179,200

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

7,000,000

Gross Profit (TTM)

7,000,000

EPS (TTM)

-1.64

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-19.29%

ROE (TTM) (>15% strong)

-0.96%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

0.0728

Previous

0.0860

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025